Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

OBJECTIVE: The aim of this study was to assess the efficiency of exenatide 2 mg/week compared with other glucagon-like peptide-1 (GLP-1) receptor agonists (dulaglutide 1.5 mg/week, liraglutide 1.2 mg/day, liraglutide 1.8 mg/day and lixisenatide 20 μg/day) in adult patients with type 2 diabetes melli...

Descripción completa

Detalles Bibliográficos
Autores principales: Capel, Margarita, Ciudin, Andreea, Mareque, María, Rodríguez-Rincón, Raquel María, Simón, Susana, Oyagüez, Itziar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248155/
https://www.ncbi.nlm.nih.gov/pubmed/31338828
http://dx.doi.org/10.1007/s41669-019-0171-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248155/
https://www.ncbi.nlm.nih.gov/pubmed/31338828
http://dx.doi.org/10.1007/s41669-019-0171-y

Ejemplares similares